[Form 4] Veracyte, Inc. Insider Trading Activity
Marc Stapley, who is listed as both Chief Executive Officer and a director of Veracyte, Inc. (VCYT), reported a non-sale withholding of 7,914 shares of common stock on 09/02/2025 at an attributable price of $30.11 per share. The withholding satisfied tax obligations arising from the vesting of restricted stock units and therefore was not a market sale. After the transaction Stapley beneficially owned 341,852 shares, which includes 529 shares purchased on 07/31/2025 under the company’s Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Marc Stapley, indicato come Chief Executive Officer e amministratore di Veracyte, Inc. (VCYT), ha riportato una ritenuta non di vendita di 7.914 azioni ordinarie il 09/02/2025 a un prezzo attribuibile di $30.11 per azione. La ritenuta è servita a coprire le imposte dovute per la maturazione di unità di azioni vincolate e pertanto non costituisce una vendita sul mercato. Dopo l’operazione Stapley deteneva utilmente 341.852 azioni, comprensive di 529 azioni acquistate il 07/31/2025 tramite il Piano di Acquisto Azionario per Dipendenti della società. Il Modulo 4 è stato firmato per procura il 09/04/2025.
Marc Stapley, registrado como Director Ejecutivo y miembro del consejo de Veracyte, Inc. (VCYT), notificó una retención no relacionada con una venta de 7.914 acciones ordinarias el 09/02/2025 a un precio atribuible de $30.11 por acción. La retención cubrió obligaciones fiscales derivadas de la consolidación de unidades restringidas de acciones y, por tanto, no fue una venta en el mercado. Tras la operación, Stapley poseía beneficiariamente 341.852 acciones, que incluyen 529 acciones adquiridas el 07/31/2025 bajo el Plan de Compra de Acciones para Empleados de la compañía. El Formulario 4 fue firmado por apoderado el 09/04/2025.
Marc Stapley는 Veracyte, Inc.(VCYT)의 최고경영자이자 이사로 등재되어 있으며, 2025-09-02에 보통주 7,914주를 매각이 아닌 원천징수 방식으로 신고했으며 주당 귀속 가격은 $30.11였습니다. 해당 원천징수는 제한조건부 주식 단위(RSU)의 권리확보로 발생한 세금 의무를 충당하기 위한 것으로 시장에서의 매각이 아닙니다. 거래 후 Stapley는 341,852주를 실질적으로 보유하고 있었고, 이에는 2025-07-31에 회사의 직원 주식구매제도를 통해 매수한 529주가 포함되어 있습니다. Form 4는 2025-09-04에 대리인이 서명했습니다.
Marc Stapley, désigné à la fois comme Chief Executive Officer et administrateur de Veracyte, Inc. (VCYT), a déclaré une retenue non liée à une vente de 7 914 actions ordinaires le 09/02/2025 à un prix attribuable de $30.11 par action. Cette retenue a servi à couvrir les obligations fiscales résultant de la consolidation d’unités d’actions restreintes et n’était donc pas une vente sur le marché. Après l’opération, Stapley détenait bénéficiairement 341 852 actions, incluant 529 actions achetées le 07/31/2025 dans le cadre du Plan d’Achat d’Actions pour Employés de la société. Le formulaire 4 a été signé par un mandataire le 09/04/2025.
Marc Stapley, als Chief Executive Officer und Direktor von Veracyte, Inc. (VCYT) geführt, meldete am 09/02/2025 eine nicht-verkaufsbedingte Einbehaltung von 7.914 Stammaktien zu einem zurechenbaren Preis von $30.11 je Aktie. Die Einbehaltung diente der Begleichung von Steuerverpflichtungen aus der Vesting-Periode eingeschränkter Aktieneinheiten und war daher kein Marktverkauf. Nach der Transaktion besaß Stapley wirtschaftlich 341.852 Aktien, darunter 529 Aktien, die am 07/31/2025 im Rahmen des Mitarbeiter-Aktienkaufplans des Unternehmens erworben wurden. Das Formular 4 wurde am 09/04/2025 von einem Bevollmächtigten unterzeichnet.
- Withholding was used to satisfy tax obligations rather than a sale, indicating the reporting person did not reduce ownership via market sale.
- Reporting shows continued significant insider ownership with 341,852 shares beneficially owned after the transaction.
- None.
Insights
TL;DR: A routine tax-withholding on RSU vesting; no sale proceeds, modest impact on insider ownership.
This report documents a common administrative transaction where 7,914 shares were withheld to satisfy tax withholding from vested restricted stock units rather than sold on the open market. The withholding reduces the reporting person’s outstanding vested shares by the withheld amount but does not alter the economic exposure from vested equity that remains held. With beneficial ownership of 341,852 shares post-transaction, the move appears routine and non-dilutive from an investor perspective.
TL;DR: Filing reflects standard executive compensation mechanics, signaling retention rather than disposition.
The Form 4 shows an administrative compliance action to cover taxes on RSU vesting, not a disposition. Such withholdings are consistent with typical equity compensation plans and indicate the reporting person retained the remaining vested shares. The filing’s clarity about the ESPP purchase and the attorney-in-fact signature meets disclosure expectations for timeliness and completeness.
Marc Stapley, indicato come Chief Executive Officer e amministratore di Veracyte, Inc. (VCYT), ha riportato una ritenuta non di vendita di 7.914 azioni ordinarie il 09/02/2025 a un prezzo attribuibile di $30.11 per azione. La ritenuta è servita a coprire le imposte dovute per la maturazione di unità di azioni vincolate e pertanto non costituisce una vendita sul mercato. Dopo l’operazione Stapley deteneva utilmente 341.852 azioni, comprensive di 529 azioni acquistate il 07/31/2025 tramite il Piano di Acquisto Azionario per Dipendenti della società. Il Modulo 4 è stato firmato per procura il 09/04/2025.
Marc Stapley, registrado como Director Ejecutivo y miembro del consejo de Veracyte, Inc. (VCYT), notificó una retención no relacionada con una venta de 7.914 acciones ordinarias el 09/02/2025 a un precio atribuible de $30.11 por acción. La retención cubrió obligaciones fiscales derivadas de la consolidación de unidades restringidas de acciones y, por tanto, no fue una venta en el mercado. Tras la operación, Stapley poseía beneficiariamente 341.852 acciones, que incluyen 529 acciones adquiridas el 07/31/2025 bajo el Plan de Compra de Acciones para Empleados de la compañía. El Formulario 4 fue firmado por apoderado el 09/04/2025.
Marc Stapley는 Veracyte, Inc.(VCYT)의 최고경영자이자 이사로 등재되어 있으며, 2025-09-02에 보통주 7,914주를 매각이 아닌 원천징수 방식으로 신고했으며 주당 귀속 가격은 $30.11였습니다. 해당 원천징수는 제한조건부 주식 단위(RSU)의 권리확보로 발생한 세금 의무를 충당하기 위한 것으로 시장에서의 매각이 아닙니다. 거래 후 Stapley는 341,852주를 실질적으로 보유하고 있었고, 이에는 2025-07-31에 회사의 직원 주식구매제도를 통해 매수한 529주가 포함되어 있습니다. Form 4는 2025-09-04에 대리인이 서명했습니다.
Marc Stapley, désigné à la fois comme Chief Executive Officer et administrateur de Veracyte, Inc. (VCYT), a déclaré une retenue non liée à une vente de 7 914 actions ordinaires le 09/02/2025 à un prix attribuable de $30.11 par action. Cette retenue a servi à couvrir les obligations fiscales résultant de la consolidation d’unités d’actions restreintes et n’était donc pas une vente sur le marché. Après l’opération, Stapley détenait bénéficiairement 341 852 actions, incluant 529 actions achetées le 07/31/2025 dans le cadre du Plan d’Achat d’Actions pour Employés de la société. Le formulaire 4 a été signé par un mandataire le 09/04/2025.
Marc Stapley, als Chief Executive Officer und Direktor von Veracyte, Inc. (VCYT) geführt, meldete am 09/02/2025 eine nicht-verkaufsbedingte Einbehaltung von 7.914 Stammaktien zu einem zurechenbaren Preis von $30.11 je Aktie. Die Einbehaltung diente der Begleichung von Steuerverpflichtungen aus der Vesting-Periode eingeschränkter Aktieneinheiten und war daher kein Marktverkauf. Nach der Transaktion besaß Stapley wirtschaftlich 341.852 Aktien, darunter 529 Aktien, die am 07/31/2025 im Rahmen des Mitarbeiter-Aktienkaufplans des Unternehmens erworben wurden. Das Formular 4 wurde am 09/04/2025 von einem Bevollmächtigten unterzeichnet.
FAQ
What did Marc Stapley report on the Form 4 for Veracyte (VCYT)?
Was the 7,914-share transaction a sale of Veracyte stock?
How many Veracyte shares did Stapley own after the transaction?
What price is reported on the Form 4 for the withheld shares?
When was the Form 4 filed or signed?
